CY1113121T1 - Υγρες συνθεσεις lh - Google Patents

Υγρες συνθεσεις lh

Info

Publication number
CY1113121T1
CY1113121T1 CY20121100836T CY121100836T CY1113121T1 CY 1113121 T1 CY1113121 T1 CY 1113121T1 CY 20121100836 T CY20121100836 T CY 20121100836T CY 121100836 T CY121100836 T CY 121100836T CY 1113121 T1 CY1113121 T1 CY 1113121T1
Authority
CY
Cyprus
Prior art keywords
liquid compositions
liquid
monodosed
pharmaceutical compositions
relates
Prior art date
Application number
CY20121100836T
Other languages
Greek (el)
English (en)
Inventor
Rita Agostinetto
Fabrizio Samaritani
Rio Alessandra Del
Joel Richard
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of CY1113121T1 publication Critical patent/CY1113121T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY20121100836T 2007-11-01 2012-09-13 Υγρες συνθεσεις lh CY1113121T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
US448107P 2007-11-28 2007-11-28
EP08844750A EP2219607B1 (en) 2007-11-01 2008-10-29 Liquid LH formulations

Publications (1)

Publication Number Publication Date
CY1113121T1 true CY1113121T1 (el) 2016-04-13

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100836T CY1113121T1 (el) 2007-11-01 2012-09-13 Υγρες συνθεσεις lh

Country Status (25)

Country Link
US (1) US8664369B2 (enExample)
EP (1) EP2219607B1 (enExample)
JP (1) JP5551601B2 (enExample)
KR (1) KR101513181B1 (enExample)
CN (1) CN101842083B (enExample)
AU (1) AU2008320844B2 (enExample)
BR (1) BRPI0818324B8 (enExample)
CA (1) CA2700662C (enExample)
CY (1) CY1113121T1 (enExample)
DK (1) DK2219607T3 (enExample)
EA (1) EA019432B1 (enExample)
EC (1) ECSP10010224A (enExample)
ES (1) ES2393233T3 (enExample)
HR (1) HRP20120660T1 (enExample)
IL (1) IL205105A (enExample)
MX (1) MX2010004639A (enExample)
MY (1) MY153976A (enExample)
NZ (1) NZ583991A (enExample)
PL (1) PL2219607T3 (enExample)
PT (1) PT2219607E (enExample)
RS (1) RS52566B (enExample)
SI (1) SI2219607T1 (enExample)
UA (1) UA101484C2 (enExample)
WO (1) WO2009056569A1 (enExample)
ZA (1) ZA201001907B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2613152T3 (es) 2008-01-09 2017-05-22 Sanofi-Aventis Deutschland Gmbh Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
CA3016451A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
SG10201403840VA (en) * 2009-07-06 2014-10-30 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
PL3345593T3 (pl) 2009-11-13 2024-04-08 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę
WO2011099036A2 (en) * 2010-02-12 2011-08-18 Intas Biopharmaceuticals Limited Liquid formulation of follicle stimulating hormone
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
DK2750699T3 (en) 2011-08-29 2015-10-26 Sanofi Aventis Deutschland A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AU2013368990B2 (en) * 2012-12-26 2017-05-18 Wockhardt Limited Pharmaceutical composition
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
KR20160104724A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
MX2016008977A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de insulina aspart estabilizadas.
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
ES2949095T3 (es) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
JP4165718B2 (ja) * 1995-03-21 2008-10-15 ラボラトワール セローノ ソシエテ アノニム ｈＣＧ液体製剤
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
WO2000004913A1 (en) * 1998-07-23 2000-02-03 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
PT1599222E (pt) * 2003-01-08 2009-06-12 Novartis Vaccines & Diagnostic Composições aquosas estabilizadas que contêm um inibidor da via do factor tecidular (tfpi) ou uma variante do inibidor da via do factor tecidular
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
RS57872B1 (sr) * 2003-04-02 2018-12-31 Ares Trading Sa Tečne farmaceutske formulacije fsh i lh zajedno sa nejonskim surfaktantom

Also Published As

Publication number Publication date
WO2009056569A1 (en) 2009-05-07
ES2393233T3 (es) 2012-12-19
WO2009056569A9 (en) 2010-01-21
KR20100088147A (ko) 2010-08-06
PL2219607T3 (pl) 2012-12-31
MY153976A (en) 2015-04-30
HRP20120660T1 (hr) 2012-09-30
JP5551601B2 (ja) 2014-07-16
US20100261649A1 (en) 2010-10-14
IL205105A0 (en) 2010-11-30
AU2008320844A1 (en) 2009-05-07
BRPI0818324B1 (pt) 2019-12-24
UA101484C2 (en) 2013-04-10
US8664369B2 (en) 2014-03-04
CA2700662A1 (en) 2009-05-07
KR101513181B1 (ko) 2015-04-21
CN101842083A (zh) 2010-09-22
EA019432B1 (ru) 2014-03-31
AU2008320844B2 (en) 2013-08-29
BRPI0818324B8 (pt) 2021-05-25
HK1145443A1 (en) 2011-04-21
MX2010004639A (es) 2010-08-04
PT2219607E (pt) 2012-08-31
IL205105A (en) 2015-04-30
ZA201001907B (en) 2011-05-25
JP2011502968A (ja) 2011-01-27
CA2700662C (en) 2015-10-13
EP2219607B1 (en) 2012-08-15
CN101842083B (zh) 2012-11-14
EA201070549A1 (ru) 2010-10-29
ECSP10010224A (es) 2010-07-30
DK2219607T3 (da) 2013-06-17
NZ583991A (en) 2012-02-24
EP2219607A1 (en) 2010-08-25
SI2219607T1 (sl) 2012-09-28
RS52566B (sr) 2013-04-30
BRPI0818324A2 (pt) 2017-05-16

Similar Documents

Publication Publication Date Title
CY1113121T1 (el) Υγρες συνθεσεις lh
CR10379A (es) Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40.
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
ATE469895T1 (de) Cgrp-rezeptorantagonisten
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
EA200802008A1 (ru) Фармацевтические композиции
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
BRPI1014956A2 (pt) agentes antinflamatórios.
EA201490644A1 (ru) Терапевтические пептиды
BRPI0919295A2 (pt) 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
MX395271B (es) Composicion farmaceutica.
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
RU2493831C3 (ru) Фармацевтические композиции
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
ECSP11011054A (es) Péptidos antivirales terapéuticos
EP2992952A4 (en) Quantitative catalytic device
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0925077A2 (pt) Conjunto dispensador.
BRPI1016190A2 (pt) compostos farmacêuticos.
UA108636C2 (xx) Пептид
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
UA115373C2 (uk) Стабільний рідкий склад amg 416 (велкалсетиду)
EP2197448A4 (en) dosing schedule